Zobrazeno 1 - 10
of 1 019
pro vyhledávání: ''
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Elotuzumab plus pomalidomide/dexamethasone (E-Pd) demonstrated efficacy and safety in relapsed and refractory multiple myeloma (RRMM). The clinical pharmacology of elotuzumab [± lenalidomide/dexamethasone (Ld)] was characterized previously.
Autor:
Nancy Chan, Jiuping Ji, Antoinette R. Tan, Janice M. Mehnert, Alice P. Chen, Jan H. Beumer, Mansi Shah, Joseph Aisner, Murugesan Gounder, Jyoti Malhotra, Rebecca A. Moss, Yong Lin, Brian F. Kiesel, Hongxia Lin, Mark N. Stein, Michael P. Kane
Publikováno v:
Cancer Chemother Pharmacol
Purpose Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus
Autor:
Dermot F. McGinnity, Diansong Zhou, Shringi Sharma, Buyun Chen, Venkatesh Pilla Reddy, Karthick Vishwanathan, Adrian J. Fretland, Joseph Ware, Yan Xu
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Limited information is available regarding the drug–drug interaction (DDI) potential of molecular targeted agents and rituximab plus cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone (R-CHOP) therapy
Autor:
Keiichiro Ishibashi, Masahito Kotaka, Toru Aoyama, Yasushi Tsuji, Naoki Nagata, Hironaga Satake, Junichi Sakamoto, Masato Nakamura, Koji Oba, Masato Kataoka, Hideyuki Mishima
Publikováno v:
Cancer Chemotherapy and Pharmacology
Background The aim of this study was to evaluate the efficacy and safety of first-line chemotherapy with re-introduction of oxaliplatin (OX) more than 6 months after adjuvant chemotherapy including OX. Methods Stage II/III colon cancer patients with
Autor:
Yoshikazu Takahashi, Hidekazu Shirota, Takashi Yoshioka, Takuhiro Yamaguchi, Kota Ouchi, Michio Kuroki, Shin Takahashi, Masahiro Takahashi, Masaki Tanaka, Masanobu Takahashi, Chikashi Ishioka, Yasuhiro Sakamoto, Hideki Shimodaira, Hiroo Imai, Satoshi Kato, Keigo Komine, Kazunori Otsuka, Hiroyuki Shibata, Hisatsugu Ohori, Hiroaki Yamaguchi, Yasushi Tsuji
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The current study aimed to determine the efficacy of trifluridine/tipiracil for elderly patients with advanced colorectal cancer. Methods This single-arm, open-label, multicenter, phase II study included elderly patients aged 65 years or more
Autor:
Carlos Becerra, Donald A. Richards, Thomas E. Boyd, Paul Conkling, Hillary H. Wu, Tracy Murray Stewart, Joe Stephenson, Daniel D. Von Hoff, Nicholas J. Vogelzang, Robert A. Casero, Lawrence Garbo, David Smith, Michael L. Fitzgerald, Robert M. Jotte, Laurence J. Marton
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: Polyamines are absolutely essential for maintaining tumor cell proliferation. PG-11047, a polyamine analogue, is a nonfunctional competitor of the natural polyamine spermine that has demonstrated anticancer activity in cells and animal model
Autor:
Pranavi Challapalli, Z. Miedzybrodzka, Madusha Meemanage, Diane Collinson, Julie Turbitt, Graeme I. Murray, Lindsay C. Spender, Mark Baxter, Russell D. Petty, Joanna Iannetta, Caroline Clark, Shaun V. Walsh
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Oesophageal squamous cell carcinoma (ESCC) has a poor prognosis. Advanced tumours are treated with fluoropyrimidine/platinum chemotherapy followed by irinotecan or taxane monotherapy, but resistance is common and new treatments are needed. Ap
Autor:
Rama Suresh, Saiama N. Waqar, Haeseong Park, Benjamin R. Tan, Nikolaos A. Trikalinos, Sarah Larson, Kerry J. Williams, Daniel Morgensztern, A. Craig Lockhart, Andrea Wang-Gillam, Jingqin Luo, Ramaswamy Govindan, Brian A. Van Tine
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: Resistance to treatment with inhibitors of mammalian target of rapamycin (mTOR) is partially mediated by activation of epidermal growth factor receptor (EGFR). We conducted a phase I study to determine the recommended phase II dose (RP2D) an
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Berzosertib (formerly M6620) is the first-in-class inhibitor of ataxia–telangiectasia and Rad3-related protein, a key component of the DNA damage response, and being developed in combination with chemotherapy for the treatment of patients w
Autor:
Elisabeth Odin, Göran Carlsson, Helena Taflin, Roger Tell, Bengt Gustavsson, Yvonne Wettergren
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The aim was to explore the correlation between increasing doses of [6R]-5,10-methylenetetrahydrofolate (arfolitixorin) and plasma concentrations of deoxyuridine (dUr) in patients with metastatic colorectal cancer (mCRC), subjected to 5-fluoro